BR112012009306A2 - método para regeneração de mielina em um paciente - Google Patents

método para regeneração de mielina em um paciente

Info

Publication number
BR112012009306A2
BR112012009306A2 BR112012009306A BR112012009306A BR112012009306A2 BR 112012009306 A2 BR112012009306 A2 BR 112012009306A2 BR 112012009306 A BR112012009306 A BR 112012009306A BR 112012009306 A BR112012009306 A BR 112012009306A BR 112012009306 A2 BR112012009306 A2 BR 112012009306A2
Authority
BR
Brazil
Prior art keywords
patient
neurodegeneration
compound
myelin
progestin compound
Prior art date
Application number
BR112012009306A
Other languages
English (en)
Inventor
Abdelmouman Ghoumari
Martine El-Etr
Michael Maria Helmut Schumacher
Rachida Guennoun
Regine Sitruk-Ware
Roberta Brinton
Original Assignee
Population Coucil Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Coucil Inc filed Critical Population Coucil Inc
Publication of BR112012009306A2 publication Critical patent/BR112012009306A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

método para regeneração de mielina em um paciente. métodos para tratar neurodegeneração e/ou mielinação em paciente são descritos que compreendem tratar o paciente com um composto de progestina que exerce a ligação aos receptores de progesterona e extrai respostas biológicas induzidas pelo receptor de progesterona sem iteragir com o receptor de androgênio e sem induzir respostas biológicas androgênicas ou de glicocorticóide em uma dosagem suficiente para prevenir ou reduzir a neurodegenaração. o composto de progestina preferivelmente compreende 16-metileno-17<244>-acetóxi-19-norpregn-4-eno-3,20-diona, e os métodos incluem combinar o composto de progestina com um composto de estrogênio para fornecer tanto a contracepção quanto o tratamento para reparo de mielina e neurodegeneração.
BR112012009306A 2009-10-19 2010-10-19 método para regeneração de mielina em um paciente BR112012009306A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932009P 2009-10-19 2009-10-19
PCT/US2010/053201 WO2011049948A2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using nestorone®

Publications (1)

Publication Number Publication Date
BR112012009306A2 true BR112012009306A2 (pt) 2016-06-07

Family

ID=43413545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009306A BR112012009306A2 (pt) 2009-10-19 2010-10-19 método para regeneração de mielina em um paciente

Country Status (9)

Country Link
US (1) US10052335B2 (pt)
EP (1) EP2490680B1 (pt)
JP (1) JP5871807B2 (pt)
AU (1) AU2010308308B2 (pt)
BR (1) BR112012009306A2 (pt)
CA (1) CA2777551C (pt)
ES (1) ES2669694T3 (pt)
MX (1) MX347890B (pt)
WO (1) WO2011049948A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2490680B1 (en) 2009-10-19 2018-04-04 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
BR112012014059B1 (pt) * 2009-12-17 2020-03-10 The Population Council Inc. Gel transdérmico de progestina / estradiol
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
CA2830519A1 (en) 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
CN102688247A (zh) * 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
US9808470B2 (en) * 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015088625A2 (en) * 2013-09-25 2015-06-18 Case Western Reserve University Compounds and methods of promoting myelination
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US20160008376A1 (en) * 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4760092A (en) * 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
ATE362382T1 (de) 2000-03-15 2007-06-15 Orbusneich Medical Inc Beschichtung welche ein anhaften von endothelzellen stimuliert
US6891081B1 (en) 2000-08-14 2005-05-10 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
WO2003041718A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003045362A2 (en) * 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
CN101232888A (zh) * 2005-03-04 2008-07-30 阿尔斯根公司 用炔诺酮及其类似物治疗肌萎缩性侧索硬化
EP2164498A4 (en) * 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2490680B1 (en) 2009-10-19 2018-04-04 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
CN102688247A (zh) 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
CN102657661A (zh) 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途

Also Published As

Publication number Publication date
CA2777551A1 (en) 2011-04-28
WO2011049948A2 (en) 2011-04-28
WO2011049948A4 (en) 2011-08-04
ES2669694T3 (es) 2018-05-28
AU2010308308B2 (en) 2013-11-28
CA2777551C (en) 2015-12-22
WO2011049948A3 (en) 2011-06-16
US10052335B2 (en) 2018-08-21
US20120231052A1 (en) 2012-09-13
MX347890B (es) 2017-05-18
AU2010308308A1 (en) 2012-06-07
JP2013508379A (ja) 2013-03-07
MX2012004542A (es) 2012-11-29
JP5871807B2 (ja) 2016-03-01
EP2490680B1 (en) 2018-04-04
EP2490680A2 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
BR112012009306A2 (pt) método para regeneração de mielina em um paciente
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010081032A3 (en) Steroidal compositions
BR112014031910A2 (pt) formulações e terapias naturais de combinação para reposição hormonal
MX2020011537A (es) Esteroides neuroactivos, composiciones y uso de los mismos.
BR112014012444A2 (pt) formulações e terapias de reposição hormonal natural combinada
MY161021A (en) Controlled release corticosteroid and methods for the treatment of otic disorders
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
WO2009132048A3 (en) Treating eosinophilic esophagitis
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2022001251A (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
BRPI0715073A8 (pt) métodos e composições para inibir a angiogênese
WO2006113242A3 (en) Method of increasing testosterone and related steroid concentrations in women
AU2009256009A8 (en) Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2011059969A3 (en) Mammalian metabolites of steroids
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2010005119A (es) Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
SE0400346D0 (sv) Steroids for cancer treatment
EP2661175A4 (en) COMBINATION STEROID AND GLUCOCORTICOID RECEPTORANT AGONIST THERAPY
IN2014CN02688A (pt)
PH12015500226B1 (en) Compositions and methods for the treatment of bone voids and open fractures
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
CR10924A (es) Metodo para estabilidad mejorada de derivados de esteroides
WO2008109719A3 (en) Steroids derivatives as selective progesterone receptor modulators

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL